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Background: Mesothelioma is invariably fatal and virtually all treat-
ments are given with the primary aim of relieving symptoms. Although 
chemotherapy is now widely used it has never been compared in a 
randomized trial with ASC alone. Two chemotherapy regimens were 
chosen for investigation: MVP and vinorelbine which had both shown 
good palliation in phase II studies.
Methods: Patients with malignant pleural mesothelioma were ran-
domized to (a) ASC alone, (b), ASC+MVP (4 x 3-weekly cycles of 
mitomycin 6mg/m2, vinblastine 6mg/m2, and cisplatin 50mg/m2), and 
(c) ASC+N (12 x weekly injections of vinorelbine 30mg/m2). ASC 
was deﬁned as regular follow-up in a specialist clinic and treatment 
could include steroids, analgesics, bronchodilators, palliative radio-
therapy, etc. The primary endpoint was overall survival, and secondary 
endpoints were response, toxicity, palliation, and quality of life (QL). 
QL was assessed by patients completing the EORTC QLQ-C30. Slow 
accrual forced a re-design from a 3-arm to a 2-arm trial by combining 
the 2 chemotherapy arms and aiming to accrue 420 patients, to reliably 
detect a 3 month improvement in median survival (76% power, 5% 
signiﬁcance level).
Results: Between 2000 and 2006 a total of 409 patients were accrued 
from 80 centres in the UK and Australia (136 ASC, 137 ASC+MVP, 
and 136 ASC+N). The median age of the patients was 65 years, 91% 
were male, 23% performance status (PS) 0, 63% PS 1, 73% epithelial 
histology, 33% stage III and 48% stage IV. The main symptoms at the 
time of randomization (reported by the clinicians as being moderate or 
severe) were: lethargy (54%), chest pain (51%), breathlessness (41%) 
and sweating (30%). In the MVP arm 61% of patients received 4 cycles 
and in the N arm 49% received at least 10 weekly cycles of vinorel-
bine. All 3 treatment groups resulted in good palliation (deﬁned as 
prevention, control or improvement) at 6 months: lethargy 59%, 51% 
and 52%, chest pain 61%, 68% and 60%, breathlessness 29%, 22% 
and 33%, and sweating 59%, 91% and 73% for ASC, ASC+MVP and 
ASC+N respectively. No differences between treatments or over time 
were observed in 4 pre-deﬁned QL subscales (physical functioning, 
dyspnoea, pain and global QL). A total of 349 patients have died, and a 
small, but non-signiﬁcant, survival beneﬁt was seen for ASC+CT (HR 
0.89, 95% CI 0.72, 1.12, p=0.32). The median and 1 year survival for 
the ASC arm was 7.6 months and 30%, and applying the HR to this, 
gave 8.5 months and 34% for the ASC+CT arm. Exploratory analyses 
by chemotherapy group suggested a survival advantage for vinorelbine 
compared with ASC (HR 0.81, 95% CI 0.63, 1.05).
Conclusions: The MRC/BTS MS01 trial is the 2nd largest ever ran-
domized trial in mesothelioma and is the ﬁrst, and likely to be the only, 
trial to compare ASC with or without chemotherapy. Although overall 
the addition of chemotherapy to ASC did not result in a statistically sig-
niﬁcant survival beneﬁt, there was a suggestion that vinorelbine should 
be investigated further.
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Background: Prior studies have demonstrated the efﬁcacy of peme-
trexed (P) alone or in combination with a platinum drug for the 
treatment of chemonaive MPM pts (Scagliotti 2003; Vogelzang 2003). 
Recent data suggests P might also be efﬁcacious for pre-treated pts with 
MPM. The P arm in a phase III study of pre-treated MPM pts yielded 
an 18.7% response rate (40.7% with stable disease, SD), 3.7 mo (95% 
CI 3.0, 4.4) median time to progressive disease (TtPD), and median 
survival time of 8.4 mos (95% CI 6.2, 10.5) (Jassem 2006). The EAP 
provided 3312 pts with access to P alone, P plus cisplatin (Cis), or P 
plus carboplatin (Cb) in 13 countries. In this abstract we report on the 
safety and efﬁcacy data of previously-treated pts with MPM.
Methods: Eligible pts had histologic or cytologic diagnosis of MPM 
and were previously treated with ≥1 line(s) of chemotherapy. Pts pre-
treated with P were allowed if they had experienced clinical beneﬁt 
from the prior P. P 500 mg/m2 alone, or in combination with either 
Cis 75 mg/m2 or Cb AUC 5, was given on day 1 of each 21-day cycle 
with standard pre-medication consisting of vitamin B12, folic acid, 
and dexamethasone. Investigator-determined best response (RR) 
and survival data (with censoring) were recorded at the end of study 
participation. Myelosuppression data (NCI CTC, version 2.0) were also 
collected.
Results: In this nonrandomized, open-label study 988 previously 
treated pts received ≥1 dose of P (493 pts), P+Cis (168 pts) or P+Cb 
(327 pts) and were evaluable for safety. Among the study participants, 
396 P pts, 151 P+Cis pts and 285 P+Cb pts were evaluable for efﬁcacy. 
Baseline characteristics, and efﬁcacy and safety data are summarized in 
the table.
Conclusion: This large study suggests that previously treated MPM pts 
can beneﬁt from treatment with P, P+Cis, and P+Cb. 
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 P P+Cis P+Cb
Median age (range) (years) 63.0 (31, 85) 59.5 (26, 77) 61.0 (25, 80)
Male (%) 75.9 75.6 81.3
Karnofsky performance status ≥ 80, 
% of pts* 74.5 81.8 81.7
RR, % of pts (95% CI) 12.1 (9.1,15.7) 23.8 (17.3, 31.4) 16.8 (12.7, 21.7)
Disease control rate (responders 
+SD), % of pts, (95% CI) 58.1 (53.0, 63.0) 67.5 (59.5, 74.9) 66.3 (60.5, 71.8)
One-year survival rate, % (95% CI) 54.7 (42.6, 66.8) 67.9 (48.6, 85.5) 65.5 (54.6, 76.5)
Median TtPD (months) (95% CI) 4.9 (4.2, 5.8) 7.4 (5.6, 10.4) 6.9 (6.2, 7.4)
Leukopenia, Gr 3/4, % of pts 13.9 11.0 18.6
Neutropenia, Gr 3/4, % of pts 15.6 19.9 31.8
Thrombocytopenia, Gr 3/4, % of pts 4.9 12.9 18.6
Anemia, Gr 3/4, % of pts 9.2 10.4 12.4
*Approximately 95% of pts in each treatment arm contributed PS data.
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Background: Tumor growth in MPM presents technical challenges in 
measuring tumor volume or response radiographically even when using 
advanced imaging techniques. Additionally, MPM is highly symptom-
atic with nearly all patients presenting with three or more symptoms. 
Of major symptoms, dyspnea is rated by patients as having the greatest 
severity (Gralla ASCO 2003). Prior analyses indicated that improve-
ment in Forced Vital Capacity (FVC) correlated with improvements in 
patient-reported dyspnea (Gralla WCLC 2005) and that radiological 
response correlated with improvements in FVC (Paoletti ASCO 2003). 
This analysis was undertaken to determine whether dyspnea and other 
PROs of the 8-item LCSS-Meso and PFTs can enhance or replace 
radiological evaluation in monitoring response to therapy.
Methods: We analyzed data from 410 patients from the randomized 
MPM trial of cisplatin ± pemetrexed (Vogelzang JCO 2003). Changes 
from baseline in PROs and FVC were calculated at the time of response 
for patients with an investigator-determined radiological major re-
sponse (PR), at ﬁrst evidence of at least stable disease (SD) for patients 
with best response of SD, or at discontinuation for patients with best 
response of progressive disease (PD). PROs considered are reported in 
the table. Changes in PROs were summarized by radiological sub-
group which were further restricted to patients with or without an FVC 
improvement of at least 5%. Discriminant analyses were conducted to 
classify patients into two groups: PR+SD vs PD using changes in PROs 
and FVC as predictors. Prediction rates from the discriminant analyses 
were calculated as the number of correctly classiﬁed patients divided 
by total sample size. 
Results: PRs alone reported smaller PRO changes than those PRs 
with 5% improvement in FVC for dyspnea, pain, and symptom 
distress. Those with PD alone reported similar change to those with 
PD and&nbsp; < 5% improvement in FVC. The highest prediction 
rate (78.4%) was achieved by a combination discriminant of patient-
reported dyspnea and FVC; however, combining either two PROs 
(ie, dyspnea and activity level) or all PROs achieved nearly the same 
prediction rate (77% and 78%, respectively).
Mean Changes from Baseline and Prediction Rates
Item
PR (n=125) 
(A)
PR and >5% 
FVC (n=49) 
(A)
PD (n=120) 
(A)
PD and <5% 
FVC (n=50) 
(A)
Prediction 
Rate (%) (B)
Dyspnea 6.4 11.6 -18.8 -21.8 73.1
Fatigue 1.5 1.9 -22.0 -22.7 71.3
Pain 11.1 16.9 -12.3 -15.1 71.0
Symptom 
distress 5.8 9.2 -16.5 -16.2 67.3
Activity level 3.7 1.8 -22.6 -22.5 71.9
Global quality 
of life 4.6 1.9 -21.6 -20.4 72.5
All PROs - - - - 78.0
FVC - - - - 67.2
Dyspnea/FVC - - - - 78.4
Dyspnea/ 
Activity level - - - - 77.0
A. Visual Analogue Scale (0-100 mm) for each PRO item. Positive value indicates improvement.
B. Number of radiological PR+SD correctly classiﬁed by discriminant plus number of radiological PD 
correctly classiﬁed by discriminant divided by total sample size; sample sizes are approximately 410 for 
PROs and 296 for FVC.
Conclusions: Changes in patient-reported LCSS-Meso items correlate 
with radiological response to therapy. PROs appear to be at least as 
sensitive in predicting response to therapy as objective measures such 
as FVC. The LCSS-Meso may serve as an effective, inexpensive, and 
easy-to-administer alternative to radiological assessment for monitor-
ing response to therapy for MPM. Prospective studies are needed to 
conﬁrm these ﬁndings.
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Background: Selected patients with limited (cT1-3N0) malignant 
pleural mesothelioma are being considered for a multimodality therapy 
with induction chemotherapy followed by extrapleural resection and 
radiotherapy. Since invasion of the mediastinal lymph nodes is a nega-
tive prognostic factor, cervical mediastinoscopy is recommended for 
staging in these patients. Transoesophageal Endoscopic Ultrasound 
with a linear scanning ultrasound endoscope and real time guided ﬁne 
needle aspiration (EUS-FNA) enables mediastinal lymph node staging 
with high accuracy in lung cancer patients. 
